Executive Overview
Pancreatic ductal adenocarcinoma (PDAC)—the most prevalent and lethal form of pancreatic cancer—stands as one of the most formidable challenges in modern oncology. Accounting for more than 80 percent of all pancreatic cancer cases, it carries a dismal five-year survival rate hovering stubbornly around 13 percent. For decades, the medical and scientific communities have focused intensely on the genetic and biochemical pathways driving this malignancy. However, traditional therapeutic interventions, including aggressive chemotherapy, radiation therapy, and surgical resection, have yielded only marginal improvements in long-term patient outcomes, largely because the vast majority of patients present with advanced disease that is inoperable or has already metastasized.
Now, a pioneering multidisciplinary team of researchers at Florida State University (FSU), spanning both the FSU College of Medicine and the FAMU-FSU College of Engineering, is pivoting toward an entirely new paradigm in cancer research: cellular physics. Backed by a substantial $2.8 million research grant from the National Cancer Institute (NCI), these scientists are launching an investigation into how physical and mechanical alterations within cells dictate the development, progression, and metastatic spread of pancreatic tumors.
By combining human-derived 3D pancreatic organoids, mechanobiology, gene-editing technologies, and mathematical modeling, the collaborative research initiative seeks to decode how the physical architecture of cells breaks down as cancer advances. Specifically, the team is investigating the collapse of microscopic internal fluid-filled spaces known as lumens, the loss of critical ion and water channels, and the subsequent activation of force-sensitive mechanotransduction proteins like Yes-associated protein (YAP). Ultimately, this project aims to expose previously hidden biomechanical vulnerabilities in pancreatic cancer, paving the way for revolutionary treatment strategies designed to outmaneuver one of humanity’s most aggressive diseases.
Detailed Chronology and Scientific Breakthroughs
The Evolution of Cellular Architecture in Cancer Progression
Changes in cellular structure and tissue organization have long served as a foundational hallmark of cancer pathology. For generations, pathologists have relied on microscopic visual assessments of tissue architecture to stage diseases and predict patient prognoses. In a normal, healthy pancreas, ductal cells arrange themselves neatly around a central hollow space called a lumen, creating a regulated fluid-filled channel that maintains proper physiological function.
However, as normal pancreatic tissue transforms into a primary tumor, and subsequently into a metastatic powerhouse, this elegant architecture undergoes drastic, pathological deformation. To map and analyze these structural transformations in real time, the FSU research team utilizes human-derived pancreatic organoids—sophisticated, miniature 3D tissue models grown in the laboratory that accurately mimic the microenvironment and structural characteristics of living human tumors.
Through comparative analysis of these organoids, the researchers have tracked a clear structural deterioration:
- Normal Organoids: Characterized by a distinct, stable central lumen surrounded by a single, thin, highly organized layer of epithelial cells.
- Primary Tumor Organoids: While maintaining a central lumen, the surrounding cellular layer thickens dramatically, reflecting unchecked cellular proliferation and early architectural disruption.
- Metastatic Tumor Organoids: The central lumen completely collapses, superseded by multiple aberrant, small lumen-like structures that mirror the chaotic, disorganized tissue architecture typical of advanced, highly aggressive human tumors.
This clear visual progression prompted the primary investigators to ask two fundamental, high-stakes questions: What biological and physical mechanisms drive these dramatic structural changes, and what are the direct consequences of these architectural shifts for cancer progression and metastasis?
[Normal Pancreatic Duct] [Primary Tumor] [Metastatic Tumor]
(Stable central lumen) --> (Thickened cell layer) --> (Collapsed lumen /
Single epithelial layer Retained central lumen Disorganized structures)Unraveling Cellular Physics: The Mechanics of Lumen Collapse
To understand why a tumor’s internal architecture collapses, the researchers turned to the principles of fluid dynamics and mechanobiology. The stability of a cellular lumen relies heavily on the precise, regulated movement of ions and water molecules across cell membranes to maintain internal fluid pressure and volume. As specific ions are actively transported into the lumen, water naturally follows via osmotic gradients, generating internal hydrostatic pressure that pushes outward against the surrounding cell wall—much like pumping air into a balloon.
When this delicate transport system fails, the internal pressure drops, and the physical forces governing the tissue are fundamentally altered. Dr. Tristan Driscoll, a mechanobiologist and assistant professor at the FAMU-FSU College of Engineering who serves as a co-investigator on the NCI grant, explains the underlying mechanics:
"A major factor driving the collapse of the lumen is the loss of ion transport that normally helps build pressure inside it, almost like filling a balloon. When that pressure changes, it also changes the mechanical forces experienced by the surrounding cells and how those cells sense and respond to those forces."
Previous investigative work conducted by the Irianto Lab identified specific ion and water channels as potential master regulators of lumen structure. In pancreatic tumor organoids, the genes responsible for encoding these essential channels are expressed at significantly lower levels than in healthy, non-cancerous pancreatic cells. Crucially, as the tumors progress in malignancy and acquire metastatic capabilities, the expression of these channel genes drops even further. This inverse correlation strongly links the loss of ion transport channels to structural collapse and aggressive cancer behavior.
To map this process thoroughly, the research team is employing advanced biophysical measurement techniques to quantify the mechanical forces exerted between neighboring epithelial cells, as well as the physical forces transmitted directly to the nuclear envelope—the protective membrane encasing the cell’s DNA. By understanding how changes in luminal pressure translate into mechanical stress on the cell nucleus, the team hopes to reveal how physical forces directly reprogram cell behavior.
The Role of Yes-Associated Protein (YAP)
A central focus of the Irianto Lab’s upcoming investigations involves a vital mechanotransduction molecule known as Yes-associated protein, or YAP. YAP functions as a molecular sensor, translating external physical forces and mechanical cues from the cellular microenvironment into internal genetic instructions.
Under normal, homeostatic cellular conditions, YAP remains sequestered outside the nucleus in an inactive state, safely away from the cell’s genetic material. However, when physical forces shift, when the extracellular matrix becomes abnormally stiffened, or when a cell experiences mechanical compression—such as the pressures generated during tumor growth and lumen collapse—YAP undergoes a conformational shift and translocates directly into the nucleus.
Once inside the nucleus, active YAP acts as a transcriptional co-activator, turning on specific genes that drive runaway cell proliferation, evasion of programmed cell death (apoptosis), and other aggressive behaviors essential for cancer survival and metastasis. Using state-of-the-art gene-editing technologies, Dr. Jerome Irianto and his team will experimentally manipulate ion and water transport pathways to observe precisely how alterations in lumen structure and YAP activity synergistically fuel pancreatic cancer progression.
Supporting Context and Metrics
To fully appreciate the urgency and scope of this $2.8 million NCI-backed initiative, it is essential to examine the epidemiological landscape of pancreatic cancer and the unique composition of the research consortium tackling the disease.
Epidemiological Burden of Pancreatic Ductal Adenocarcinoma (PDAC)
| Metric / Indicator | Statistical Value | Clinical Implication |
|---|---|---|
| Disease Prevalence | > 80% of all pancreatic cancers | PDAC is overwhelmingly the most common form of the disease, making it the primary target for therapeutic research. |
| Mortality Ranking | 3rd leading cause of cancer deaths in the U.S. | Outpaces many other major cancers in lethality, claiming tens of thousands of American lives annually. |
| Five-Year Survival Rate | Approximately 13% | Reflects a severe lack of early detection methods and limited efficacy of current standard-of-care treatments. |
| Surgical Eligibility | Minority of patients | Most patients present with locally advanced or metastatic tumors that cannot be surgically excised. |
A Multidisciplinary Collaborative Consortium
Solving a complex biophysical puzzle like cancer metastasis requires a departure from traditional, siloed academic research. The FSU-led initiative bridges multiple scientific disciplines, bringing together world-class experts across engineering, molecular biology, cancer research, mathematical modeling, and clinical pathology:
- Dr. Jerome Irianto: Assistant Professor of Biomedical Sciences at the FSU College of Medicine, specializing in cellular mechanics and nuclear architecture in cancer.
- Dr. Tristan Driscoll: Assistant Professor at the FAMU-FSU College of Engineering, bringing advanced expertise in mechanobiology and cellular forces.
- Dr. Katarzyna Rejniak: Mathematical modeler from the Moffitt Cancer Center, tasked with simulating tumor mechanics and cellular organization computationally.
- Dr. Chang-il Hwang: Pancreatic cancer biologist from the University of California, Davis, providing deep expertise in pancreatic tumor initiation and progression models.
- Dr. Jose I. Diaz: Pathologist at the FSU College of Medicine, bridging laboratory organoid models with real-world human tissue pathology.
By integrating empirical wet-lab biology with rigorous mathematical modeling and clinical pathology, this cross-institutional team aims to uncover dimensions of pancreatic tumorigenesis that remain entirely invisible when studying genes or biochemical signaling pathways in isolation.
Official Statements
The launch of this high-impact research initiative has drawn strong institutional support from leadership at Florida State University, underscoring the vital intersection of engineering and medicine in addressing critical health crises.
Reflecting on the overarching mission of the project, Dr. Jerome Irianto emphasized the ultimate clinical goal of the research team:
"Our goal is to reveal new vulnerabilities in pancreatic cancer that could shape future treatment strategies. Despite advancements in care, this continues to be an especially deadly disease that kills tens of thousands of people every year. The better we understand how this works within cells, the better we will be at stopping it."
Dr. Tristan Driscoll highlighted the transformative shift in perspective that mechanobiology brings to oncology, noting that understanding physical forces within tissues opens entirely new avenues for intervention:
"When that pressure changes, it also changes the mechanical forces experienced by the surrounding cells and how those cells sense and respond to those forces. By looking at the physical collapse of the tissue as an active driver of disease rather than a mere side effect, we can begin to design strategies that interrupt these mechanical signaling cascades."
Future Outlook and Therapeutic Implications
As the FSU research team embarks on this multi-year investigation funded by the National Cancer Institute, the implications extend far beyond the academic laboratory. If the team successfully proves that ion channel degradation, lumen collapse, and YAP activation are master drivers of pancreatic cancer metastasis, it will establish an entirely new class of therapeutic targets.
Historically, pharmaceutical drug development for pancreatic cancer has concentrated almost exclusively on targeting mutated oncogenes or inhibiting biochemical signaling cascades using small molecules and monoclonal antibodies. Unfortunately, pancreatic tumors are notoriously adept at developing drug resistance by rewiring these biochemical networks.
Targeting the physical properties of tumors—such as mechanotransduction pathways, cellular ion transport, and intracellular pressure regulation—represents a fundamentally different approach. Cancer cells cannot easily mutate their way out of physical laws such as osmotic pressure, fluid dynamics, and mechanical tension. By developing pharmacological agents that restore normal ion transport, prevent luminal collapse, or block YAP nuclear translocation, future therapies could potentially force metastatic cancer cells back into a benign, organized, and manageable state.
As the multidisciplinary team at Florida State University, UC Davis, and the Moffitt Cancer Center begins combining organoid models with advanced mathematical simulations, the medical community watches with cautious optimism. In the relentless war against pancreatic cancer, these insights into cellular physics may soon provide the critical wedge needed to crack open the disease’s defenses and dramatically improve patient survival.
0 Comments